Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Casalegno Garduño, Rosaely [VerfasserIn]   i
 Schmitt, Anita [VerfasserIn]   i
 Spitschak, Alf [VerfasserIn]   i
 Greiner, Jochen [VerfasserIn]   i
 Wang, Lei [VerfasserIn]   i
 Hilgendorf, Inken [VerfasserIn]   i
 Hirt, Carsten [VerfasserIn]   i
 Ho, Anthony Dick [VerfasserIn]   i
 Freund, Mathias [VerfasserIn]   i
 Schmitt, Michael [VerfasserIn]   i
Titel:Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation
Verf.angabe:Rosaely Casalegno‐Garduño, Anita Schmitt, Alf Spitschak, Jochen Greiner, Lei Wang, Inken Hilgendorf, Carsten Hirt, Anthony D. Ho, Mathias Freund and Michael Schmitt
Jahr:2016
Jahr des Originals:2015
Umfang:10 S.
Fussnoten:Online 31 October 2015 ; Gesehen am 13.02.2020
Titel Quelle:Enthalten in: International journal of cancer
Ort Quelle:Bognor Regis : Wiley-Liss, 1966
Jahr Quelle:2016
Band/Heft Quelle:138(2016), 7, Seite 1792-1801
ISSN Quelle:1097-0215
Abstract:Wilms' tumor gene 1 (WT1) is overexpressed in leukemia and WT1-derived CD8+ T-cell epitopes for immunotherapies targeting WT1 have been defined. Here, we analyzed expression of WT1 in 226 peripheral blood and bone marrow samples from patients with acute myeloid leukemia or myelodysplastic syndrome (AML/MDS) before and after allogeneic stem cell transplantation (SCT). Transcripts were assessed by quantitative polymerase chain reaction, and WT1-specific CD8+ cytotoxic T cells (CTL) were monitored by tetramer staining and enzyme-linked immunospot (ELISPOT) assays. Reduction of WT1 levels correlated with a longer survival (p < 0.01). Increment of WT1 transcripts eventually resulted in relapse and subsequent death of the patients. In patients with longer survival and continuous complete remission (cCR) after SCT, higher and enduring frequencies of WT1-specific CTL than in patients developing a relapse were detected. These cells were effector T cells secreting interferon gamma and granzyme B. In summary, WT1 is a suitable marker for the detection of minimal residual disease after SCT or chemotherapy. A rising WT1 signal correlated with a dismal prognosis of the patients. WT1-specific CD8+ T cells might contribute to the maintenance of a cCR. Targeting WT-1 by peptide/protein vaccination as well as adoptive transfer of genetically modified T cells are future options in the individualized therapy for AML/MDS patients.
DOI:doi:10.1002/ijc.29909
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1002/ijc.29909
 Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.29909
 DOI: https://doi.org/10.1002/ijc.29909
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:AML
 MDS
 specific T cells
 WT1
K10plus-PPN:1689992824
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68488572   QR-Code
zum Seitenanfang